DADE BEHRING INC
10-Q, EX-27, 2000-08-14
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: DADE BEHRING INC, 10-Q, 2000-08-14
Next: THCG INC, 10-Q, 2000-08-14



<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>                       <C>
<PERIOD-TYPE>                   3-MOS                     6-MOS
<FISCAL-YEAR-END>                         DEC-31-2000               DEC-31-2000
<PERIOD-START>                            APR-01-2000               JAN-01-2000
<PERIOD-END>                              JUN-30-2000               JUN-30-2000
<CASH>                                         26,700                    26,700
<SECURITIES>                                        0                         0
<RECEIVABLES>                                 327,400                   327,400
<ALLOWANCES>                                        0                         0
<INVENTORY>                                   254,000                   254,000
<CURRENT-ASSETS>                              701,100                   701,100
<PP&E>                                        350,000                   350,000
<DEPRECIATION>                                      0                         0
<TOTAL-ASSETS>                              1,644,100                 1,644,100
<CURRENT-LIABILITIES>                         315,400                   315,400
<BONDS>                                             0                         0
                               0                         0
                                         0                         0
<COMMON>                                            0                         0
<OTHER-SE>                                  (176,700)                 (176,700)
<TOTAL-LIABILITY-AND-EQUITY>                1,644,100                 1,644,100
<SALES>                                       310,200                   598,800
<TOTAL-REVENUES>                              310,200                   598,800
<CGS>                                         148,700                   273,900
<TOTAL-COSTS>                                 154,100                   297,100
<OTHER-EXPENSES>                              (2,800)                   (1,800)
<LOSS-PROVISION>                                    0                         0
<INTEREST-EXPENSE>                             36,200                    69,800
<INCOME-PRETAX>                              (26,000)                  (40,200)
<INCOME-TAX>                                  (6,500)                  (12,200)
<INCOME-CONTINUING>                          (19,500)                  (28,000)
<DISCONTINUED>                                      0                         0
<EXTRAORDINARY>                                     0                         0
<CHANGES>                                           0                         0
<NET-INCOME>                                 (19,500)                  (28,000)
<EPS-BASIC>                                         0                         0
<EPS-DILUTED>                                       0                         0


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission